Dexamethasone and severe head injury. A prospective double-blind study

Area of Science:

• Neurology
• Critical Care Medicine

Background:

• Severe head injuries represent a significant cause of morbidity and mortality.
• Corticosteroids, like dexamethasone, have been investigated for their potential to mitigate secondary brain injury.

Purpose of the Study:

• To evaluate the efficacy of dexamethasone in improving outcomes for patients with severe head injuries.
• To determine if dexamethasone affects intracranial pressure or neurological status during hospitalization.

Main Methods:

• A prospective, double-blind, placebo-controlled study.
• Patients with severe head injuries were stratified by injury severity and received placebo, low-dose (16 mg/day), or high-dose (96 mg/day) dexamethasone for 6 days.
• Outcomes were assessed at 6 months post-injury.

Main Results:

• No statistically significant differences in good outcome rates were observed between placebo (37%), low-dose (44%), and high-dose (29%) dexamethasone groups.
• Dexamethasone did not significantly impact intracranial pressure patterns or serial neurological examinations.
• Good outcomes were associated with younger age, less severe coma on admission, and preserved brain-stem reflexes.

Conclusions:

• Dexamethasone, in both high and low dosages, demonstrated no significant effect on morbidity or mortality in patients with severe head injuries.
• Recurrent intracranial hematomas and diffuse brain injuries were primary causes of death, unaffected by corticosteroid therapy.
• Previous studies suggesting corticosteroid benefits require re-evaluation, as this study found no significant outcome improvement.